Q4 2022 Results
Company overview
Financial review
2023 priorities
Appendix
PluvictoⓇ rapid uptake in US reflects very strong demand,
driven by significant unmet need and impressive clinical profile
Sales evolution
Global sales, USD m
80
60
179
2
Q1
10
10
Q2
Q3
Q4
2022
NBRX new to brand prescriptions. mCRPC metastatic castration-resistant prostate cancer.
31 Investor Relations | Q4 2022 Results
GROWTH
PLUVICTO
FY sales USD 271 million (almost entirely US)
NBRx share 18% in post-taxane mCRPC
160+ unique accounts in US treated with Pluvicto in 2022
More than 75% of insured lives covered
(across Medicare, Medicaid and private payers)
Permanent A code effective in October
Approved in EU for mCRPC post-taxane
NOVARTIS | Reimagining MedicineView entire presentation